LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 6 of total 6

Search options

  1. Article ; Online: Génétique constitutionnelle et risque de cancer du sein.

    Goldbarg, Veronica / Caron, Olivier

    La Revue du praticien

    2021  Volume 70, Issue 7, Page(s) 730–732

    Title translation Germline mutations and breast cancer risk.
    MeSH term(s) Breast ; Breast Neoplasms/epidemiology ; Breast Neoplasms/genetics ; Genetic Predisposition to Disease ; Germ-Line Mutation ; Humans
    Language French
    Publishing date 2021-03-19
    Publishing country France
    Document type Journal Article
    ZDB-ID 205365-2
    ISSN 2101-017X ; 0035-2640
    ISSN (online) 2101-017X
    ISSN 0035-2640
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Ua VI Zs.433: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: Malignant Adenomyoepithelioma of the Breast: An Unexpected Malignancy in a Lynch Syndrome Patient.

    Joyon, Natacha / Guillaume, Zoe / Ouafi, Lamia / Cotteret, Sophie / Rouleau, Etienne / Caron, Olivier / Goldbarg, Veronica / Lacroix-Triki, Magali

    International journal of surgical pathology

    2022  Volume 31, Issue 5, Page(s) 572–575

    MeSH term(s) Humans ; Female ; Adenomyoepithelioma/diagnosis ; Adenomyoepithelioma/surgery ; Adenomyoepithelioma/pathology ; Colorectal Neoplasms, Hereditary Nonpolyposis/complications ; Colorectal Neoplasms, Hereditary Nonpolyposis/diagnosis ; Breast/surgery ; Breast/pathology ; Breast Neoplasms
    Language English
    Publishing date 2022-06-16
    Publishing country United States
    Document type Journal Article
    ZDB-ID 1336393-1
    ISSN 1940-2465 ; 1066-8969
    ISSN (online) 1940-2465
    ISSN 1066-8969
    DOI 10.1177/10668969221105623
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 4500: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article ; Online: Pertuzumab: development beyond breast cancer.

    Barthélémy, Philippe / Leblanc, Julie / Goldbarg, Veronica / Wendling, Frédérique / Kurtz, Jean-Emmanuel

    Anticancer research

    2014  Volume 34, Issue 4, Page(s) 1483–1491

    Abstract: Pertuzumab (Perjeta®) represents the first monoclonal antibody in a new class of agents known as dimerization inhibitors. Pertuzumab was recently approved for the treatment of Human Epidermal Receptor 2 (HER2)-positive breast cancer in the metastatic and ...

    Abstract Pertuzumab (Perjeta®) represents the first monoclonal antibody in a new class of agents known as dimerization inhibitors. Pertuzumab was recently approved for the treatment of Human Epidermal Receptor 2 (HER2)-positive breast cancer in the metastatic and neo-adjuvant setting. This approval for first-line therapy for metastatic breast cancer was based on the results of a large randomized multicenter phase III trial showing a significant improvement in overall survival when pertuzumab was combined with trastuzumab and docetaxel in HER2-positive metastatic breast cancer. In the neoadjuvant setting, dual HER2 blockade by trastuzumab and pertuzumab improved the complete pathological response rate. However, pertuzumab development was not confined to breast cancer and in the present article, we focus on pertuzumab data for solid tumors other than breast cancer, and review the biological rationale for its use, the published pre-clinical and clinical evidence, as well ongoing trials.
    MeSH term(s) Animals ; Antibodies, Monoclonal, Humanized/therapeutic use ; Antineoplastic Agents/therapeutic use ; Breast Neoplasms/drug therapy ; Breast Neoplasms/genetics ; Breast Neoplasms/metabolism ; Clinical Trials, Phase I as Topic ; Clinical Trials, Phase II as Topic ; Clinical Trials, Phase III as Topic ; Drug Evaluation, Preclinical ; Female ; Humans ; Multigene Family ; Receptor, ErbB-2/antagonists & inhibitors ; Receptor, ErbB-2/genetics ; Receptor, ErbB-2/metabolism
    Chemical Substances Antibodies, Monoclonal, Humanized ; Antineoplastic Agents ; Receptor, ErbB-2 (EC 2.7.10.1) ; pertuzumab (K16AIQ8CTM)
    Language English
    Publishing date 2014-04
    Publishing country Greece
    Document type Journal Article ; Review
    ZDB-ID 604549-2
    ISSN 1791-7530 ; 0250-7005
    ISSN (online) 1791-7530
    ISSN 0250-7005
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1642: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article ; Online: Adherence and patients' attitudes to oral anticancer drugs: a prospective series of 201 patients focusing on targeted therapies.

    Barthélémy, Philippe / Asmane-De la Porte, Irène / Meyer, Nicolas / Duclos, Brigitte / Serra, Sebastian / Dourthe, Louis-Marie / Amé, Shanti / Litique, Valère / Giron, Cathy / Goldbarg, Veronica / Fornecker, Luc / Quoix, Elisabeth / Kurtz, Jean-Emmanuel

    Oncology

    2015  Volume 88, Issue 1, Page(s) 1–8

    Abstract: Objectives: Patient adherence is a challenge in oncology and hematology practice. Hormone therapy data in breast cancer suggest insufficient adherence and poor persistence. Limited data are available for targeted therapies (TT) including tyrosine kinase ...

    Abstract Objectives: Patient adherence is a challenge in oncology and hematology practice. Hormone therapy data in breast cancer suggest insufficient adherence and poor persistence. Limited data are available for targeted therapies (TT) including tyrosine kinase and mammalian target of rapamycin inhibitors.
    Methods: We performed a prospective survey using a 15-item questionnaire in patients with solid tumors and hematologic malignancies receiving oral anticancer therapy. Treatment duration, setting (adjuvant vs. metastatic), cancer type, age, and comedication were recorded.
    Results: 201 patients (median age 65.5 years) participated, 102 with TT and 99 with hormone therapy or chemotherapy (HC). The median time of drug intake was 11.0 months. Written information was more frequently given to TT patients (68.6 vs. 23.2%, p < 0.0001). TT and HC patients showed equal adherence to therapy (72.5 vs. 69.6%, p = n.s.) despite TT patients experiencing more side effects (p < 0.0001) and taking more concomitant oral medication (p = 0.0042). Forgotten doses were the leading cause of nonadherence in HC patients (83%, as compared to 54% in the TT group), whereas dose reduction by the patient was higher in the TT group (32 vs. 17%).
    Conclusions: Despite advances in providing information to patients leading to better adherence among TT patients, efforts towards better patient education are warranted including dedicated staff for monitoring outpatient anticancer oral therapy.
    MeSH term(s) Administration, Oral ; Adult ; Age Factors ; Aged ; Aged, 80 and over ; Antineoplastic Agents/adverse effects ; Antineoplastic Agents/therapeutic use ; Attitude ; Humans ; Medication Adherence ; Middle Aged ; Molecular Targeted Therapy ; Neoplasms/drug therapy ; Prospective Studies ; Surveys and Questionnaires
    Chemical Substances Antineoplastic Agents
    Language English
    Publishing date 2015
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 250101-6
    ISSN 1423-0232 ; 0030-2414
    ISSN (online) 1423-0232
    ISSN 0030-2414
    DOI 10.1159/000366226
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Uh III Zs.151: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article: Adherence and Patients' Attitudes to Oral Anticancer Drugs: A Prospective Series of 201 Patients Focusing on Targeted Therapies

    Barthélémy, Philippe / Asmane-De la Porte, Irène / Meyer, Nicolas / Duclos, Brigitte / Serra, Sebastian / Dourthe, Louis-Marie / Amé, Shanti / Litique, Valère / Giron, Cathy / Goldbarg, Veronica / Fornecker, Luc / Quoix, Elisabeth / Kurtz, Jean-Emmanuel

    Oncology

    2014  Volume 88, Issue 1, Page(s) 1–8

    Abstract: Objectives: Patient adherence is a challenge in oncology and hematology practice. Hormone therapy data in breast cancer suggest insufficient adherence and poor persistence. Limited data are available for targeted therapies (TT) including tyrosine kinase ... ...

    Institution Pôle d'Oncologie et d'Hématologie Service de Santé Publique, and Pôle des Pathologies Thoraciques, Hôpitaux Universitaires de Strasbourg Laboratoire de biostatistique, Faculté de Médecine de Strasbourg Clinique Ste Anne, and Federation of Translational Research INSERM U 1113 and EA 3430, University of Strasbourg, Strasbourg, and Service d'Oncologie et d'Hématologie, CHG Pasteur, Colmar, France
    Abstract Objectives: Patient adherence is a challenge in oncology and hematology practice. Hormone therapy data in breast cancer suggest insufficient adherence and poor persistence. Limited data are available for targeted therapies (TT) including tyrosine kinase and mammalian target of rapamycin inhibitors. Methods: We performed a prospective survey using a 15-item questionnaire in patients with solid tumors and hematologic malignancies receiving oral anticancer therapy. Treatment duration, setting (adjuvant vs. metastatic), cancer type, age, and comedication were recorded. Results: 201 patients (median age 65.5 years) participated, 102 with TT and 99 with hormone therapy or chemotherapy (HC). The median time of drug intake was 11.0 months. Written information was more frequently given to TT patients (68.6 vs. 23.2%, p < 0.0001). TT and HC patients showed equal adherence to therapy (72.5 vs. 69.6%, p = n.s.) despite TT patients experiencing more side effects (p < 0.0001) and taking more concomitant oral medication (p = 0.0042). Forgotten doses were the leading cause of nonadherence in HC patients (83%, as compared to 54% in the TT group), whereas dose reduction by the patient was higher in the TT group (32 vs. 17%). Conclusions: Despite advances in providing information to patients leading to better adherence among TT patients, efforts towards better patient education are warranted including dedicated staff for monitoring outpatient anticancer oral therapy.
    Keywords Oral chemotherapy ; Targeted therapies ; Cancer ; Adherence
    Language English
    Publishing date 2014-09-18
    Publisher S. Karger AG
    Publishing place Basel, Switzerland
    Document type Article
    Note Clinical Study
    ZDB-ID 250101-6
    ISSN 1423-0232 ; 0030-2414
    ISSN (online) 1423-0232
    ISSN 0030-2414
    DOI 10.1159/000366226
    Database Karger publisher's database

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Uh III Zs.151: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  6. Article ; Online: Classification of 101 BRCA1 and BRCA2 variants of uncertain significance by cosegregation study: A powerful approach.

    Caputo, Sandrine M / Golmard, Lisa / Léone, Mélanie / Damiola, Francesca / Guillaud-Bataille, Marine / Revillion, Françoise / Rouleau, Etienne / Derive, Nicolas / Buisson, Adrien / Basset, Noémie / Schwartz, Mathias / Vilquin, Paul / Garrec, Celine / Privat, Maud / Gay-Bellile, Mathilde / Abadie, Caroline / Abidallah, Khadija / Airaud, Fabrice / Allary, Anne-Sophie /
    Barouk-Simonet, Emmanuelle / Belotti, Muriel / Benigni, Charlotte / Benusiglio, Patrick R / Berthemin, Christelle / Berthet, Pascaline / Bertrand, Ophelie / Bézieau, Stéphane / Bidart, Marie / Bignon, Yves-Jean / Birot, Anne-Marie / Blanluet, Maud / Bloucard, Amelie / Bombled, Johny / Bonadona, Valerie / Bonnet, Françoise / Bonnet-Dupeyron, Marie-Noëlle / Boulaire, Manon / Boulouard, Flavie / Bouras, Ahmed / Bourdon, Violaine / Brahimi, Afane / Brayotel, Fanny / Bressac de Paillerets, Brigitte / Bronnec, Noémie / Bubien, Virginie / Buecher, Bruno / Cabaret, Odile / Carriere, Jennifer / Chiesa, Jean / Chieze-Valéro, Stephanie / Cohen, Camille / Cohen-Haguenauer, Odile / Colas, Chrystelle / Collonge-Rame, Marie-Agnès / Conoy, Anne-Laure / Coulet, Florence / Coupier, Isabelle / Crivelli, Louise / Cusin, Véronica / De Pauw, Antoine / Dehainault, Catherine / Delhomelle, Hélène / Delnatte, Capucine / Demontety, Sophie / Denizeau, Philippe / Devulder, Pierre / Dreyfus, Helene / d'Enghein, Catherine Dubois / Dupré, Anaïs / Durlach, Anne / Dussart, Sophie / Fajac, Anne / Fekairi, Samira / Fert-Ferrer, Sandra / Fiévet, Alice / Fouillet, Robin / Mouret-Fourme, Emmanuelle / Gauthier-Villars, Marion / Gesta, Paul / Giraud, Sophie / Gladieff, Laurence / Goldbarg, Veronica / Goussot, Vincent / Guibert, Virginie / Guillerm, Erell / Guy, Christophe / Hardouin, Agnès / Heude, Céline / Houdayer, Claude / Ingster, Olivier / Jacquot-Sawka, Caroline / Jones, Natalie / Krieger, Sophie / Lacoste, Sofiane / Lallaoui, Hakima / Larbre, Helene / Laugé, Anthony / Le Guyadec, Gabrielle / Le Mentec, Marine / Lecerf, Caroline / Le Gall, Jessica / Legendre, Bérengère / Legrand, Clémentine / Legros, Angélina / Lejeune, Sophie / Lidereau, Rosette / Lignon, Norbert / Limacher, Jean-Marc / Doriane Livon / Lizard, Sarab / Longy, Michel / Lortholary, Alain / Macquere, Pierre / Mailliez, Audrey / Malsa, Sarah / Margot, Henri / Mari, Véronique / Maugard, Christine / Meira, Cindy / Menjard, Julie / Molière, Diane / Moncoutier, Virginie / Moretta-Serra, Jessica / Muller, Etienne / Nevière, Zoe / Nguyen Minh Tuan, Thien-Vu / Noguchi, Tetsuro / Noguès, Catherine / Oca, Florine / Popovici, Cornel / Prieur, Fabienne / Raad, Sabine / Rey, Jean-Marc / Ricou, Agathe / Salle, Lucie / Saule, Claire / Sevenet, Nicolas / Simaga, Fatoumata / Sobol, Hagay / Suybeng, Voreak / Tennevet, Isabelle / Tenreiro, Henrique / Tinat, Julie / Toulas, Christine / Turbiez, Isabelle / Uhrhammer, Nancy / Vande Perre, Pierre / Vaur, Dominique / Venat, Laurence / Viellard, Nicolas / Villy, Marie-Charlotte / Warcoin, Mathilde / Yvard, Alice / Zattara, Helene / Caron, Olivier / Lasset, Christine / Remenieras, Audrey / Boutry-Kryza, Nadia / Castéra, Laurent / Stoppa-Lyonnet, Dominique

    American journal of human genetics

    2021  Volume 108, Issue 10, Page(s) 1907–1923

    Abstract: Up to 80% of BRCA1 and BRCA2 genetic variants remain of uncertain clinical significance (VUSs). Only variants classified as pathogenic or likely pathogenic can guide breast and ovarian cancer prevention measures and treatment by PARP inhibitors. We ... ...

    Abstract Up to 80% of BRCA1 and BRCA2 genetic variants remain of uncertain clinical significance (VUSs). Only variants classified as pathogenic or likely pathogenic can guide breast and ovarian cancer prevention measures and treatment by PARP inhibitors. We report the first results of the ongoing French national COVAR (cosegregation variant) study, the aim of which is to classify BRCA1/2 VUSs. The classification method was a multifactorial model combining different associations between VUSs and cancer, including cosegregation data. At this time, among the 653 variants selected, 101 (15%) distinct variants shared by 1,624 families were classified as pathogenic/likely pathogenic or benign/likely benign by the COVAR study. Sixty-six of the 101 (65%) variants classified by COVAR would have remained VUSs without cosegregation data. Of note, among the 34 variants classified as pathogenic by COVAR, 16 remained VUSs or likely pathogenic when following the ACMG/AMP variant classification guidelines. Although the initiation and organization of cosegregation analyses require a considerable effort, the growing number of available genetic tests results in an increasing number of families sharing a particular variant, and thereby increases the power of such analyses. Here we demonstrate that variant cosegregation analyses are a powerful tool for the classification of variants in the BRCA1/2 breast-ovarian cancer predisposition genes.
    MeSH term(s) BRCA1 Protein/genetics ; BRCA2 Protein/genetics ; Breast Neoplasms/classification ; Breast Neoplasms/genetics ; Breast Neoplasms/pathology ; Female ; Genetic Predisposition to Disease ; Genetic Testing ; Genetic Variation ; Genotype ; Humans ; Ovarian Neoplasms/classification ; Ovarian Neoplasms/genetics ; Ovarian Neoplasms/pathology
    Chemical Substances BRCA1 Protein ; BRCA1 protein, human ; BRCA2 Protein ; BRCA2 protein, human
    Language English
    Publishing date 2021-09-30
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 219384-x
    ISSN 1537-6605 ; 0002-9297
    ISSN (online) 1537-6605
    ISSN 0002-9297
    DOI 10.1016/j.ajhg.2021.09.003
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 107: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top